Serotonin and panic

British Journal of Psychiatry

Volumn 172, Issue JUNE, 1998, Pages 465-471

  Bell, C J ^a   Nutt, D J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FLUOXETINE; FLUVOXAMINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; ZIMELDINE;

COGNITION; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; HUMAN; NEUROTRANSMITTER RELEASE; NONHUMAN; PANIC; REVIEW; SEROTONIN RELEASE;

EID: 0031861748     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.172.6.465     Document Type: Review

References (42)

1. Bakish, D., McNair, N. V. P., Saxena, B., et al (1994) A double-blind comparison of fluvoxamine, imipramine and placebo in the treatment of out-patients with panic disorder. Neuropsychopharmacology, 10 (suppl. 3), 11s.
2. Black, D. W., Wesner, R., Bowers, W., et al (1993) A comparison of fluvoxamine, cognitive therapy and placebo in the treatment of panic disorder. Archives of General Psychiatry, 50, 44-50.
3. Blier, P., de Montigny, C. & Chaput, Y. (1990) A role for the serotonergic system in the mechanism of action of antidepressant treatments; preclinical evidence. Journal of Clinical Psychiatry, 6 (suppl. 5), 5-12.
4. Charney, D. S. & Heninger, G. (1986) Serotonin function in panic disorder. Archives of General Psychiatry, 43, 1059-1065.
5. _, Woods, S. W., Goodman, W. K., et al (1986) Drug treatment of panic disorder; the comparative efficacy of imipramine, alprazolam and trazadone. Journal of Clinical Psychiatry, 47, 580-586.
6. _, _, _, et al (1987) Serotonin function in anxiety: II. Effects of the serotonin agonist m-CPP in panic disorder patients and healthy subjects. Psychopharmacology, 92, 14-24.
7. Deakin, J. F. W. & Graeff, F. G. (1991) 5-HT and mechanisms of defence. Journal of Psychopharmacology, 5, 305-315.
8. De Beurs, E., van Balkom, A., Lange, A., et al (1995) Treatment of panic disorder with agoraphobia; comparison of fluvoxamine, placebo and psychological panic management combined with exposure and of exposure in vivo alone. American Journal of Psychiatry, 152, 683-691.
9. Delgado, P. L., Charney, D. S., Price, L. H., et al (1990) Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant induced remission by rapid depletion of plasma tryptophan. Archives of General Psychiatry, 47, 411-417.
10. Den Boer, J., Westenberg, H. & Kamerbeek, W. (1987) Effect of SSRIs in anxiety disorders; a double blind comparison of fluvoxamine and clomipramine. International Clinical Psychopharmacology, 2, 21-32.
11. _ & _ (1988) Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: a double blind comparative study with fluvoxamine and maprotiline. International Clinical Psychopharmacology, 3, 59-74.
12. _ & _ (1990) Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology, 102, 85-94.
13. Dunbar, G., Steiner, M., Oakes, R., et al (1995) A fixed dose study of paroxetine (10 mg, 20 mg, 40 mg) and placebo in the treatment of panic disorder. European Neuropsychopharmacology, 5, 361.
14. Engelman, K., Lovenberg, W., Sjoerdsman, A., et al (1967) Inhibition of 5-HT synthesis by p-chlorophenylalanine in carcinoid syndrome. New England Journal of Medicine, 227, 1103-1108.
15. Evans, L., Kenardy, J., Schneider, P., et al (1986) Effect of a selective serotonin reuptake inhibitor in agoraphobia with panic attacks. Acta Psychiatrica Scandinavian, 73, 49-53.
16. George, D. T., Nutt, D. J., Rawlings, R. R., et al (1995) Behavioural and endocrine responses to clomipramine in panic disorder patients with and without alcoholism. Biological Psychiatry, 37, 112-119.
17. Goddard, A. W., Sholomskas, D. E. & Walton, K. E. (1994) Effects of tryptophan depletion in panic disorder. Biological Psychiatry, 36, 775-777.
18. Graeff, F. G. (1990) Brain defense systems and anxiety. In Handbook of Anxiety, Vol. 3: The Neurobiology of Anxiety (eds M. Roth, G. D. Burrows & R. Noyes), pp. 307-354, Amsterdam: Elsevier.
19. _, Zuardi, A. W., Gjimiglio, J. S., et al (1985) Effect of metergoline on human anxiety. Psychopharmacology, 86, 334-338.
20. _, Guimeras, T. S. & De Andrade, T.G. (1996) Role of 5-HT in stress, anxiety and depression. Pharmacology, Biochemistry and Behaviour, 54, 129-141.
21. Hoehn-Saric, R., Mcleod, D. R. & Hipsley, P. A. (1993) Effect of fluvoxamine on panic disorder. Journal of Clinical Psychopharmacology, 13, 321-326.
22. Jenck, F., Martin, J. R. & Moreau, J. L. (1996) Animal models of panic disorder - emphasis on face and predictive validity. European Neuropsychopharmacology, 6 (suppl. 4), s22.01.
23. Johnson, M. R., Lydiard, R. B. & Ballenger, J. C. (1995) Panic disorder: Pathophysiology and drug treatment. Drugs, 49, 328-344.
24. Kahn, R. S., Wetzler, S. & van Pragg, H. M. (1988) Behavioural indications for receptor hypersensitivity in panic disorder. Psychiatry Research, 25, 101-104.
25. Lecrubier, Y., Bakker, A. & The Collaborative Paroxetine Panic Study Investigators (1997a) A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatrica Scandinavica, 95, 145-152.
26. _, Judge, R. & The Collaborative Paroxetine Panic Study Investigators (1997b) Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatrica Scandinavica, 95, 153-160.
27. 1a receptor effector system responsivity in panic disorder. Psychopharmacology, 106, 111-117.
28. Mavissakalian, M. & Perel, I. M. (1988) Imipramine dose reponse relationship in panic disorder with agoraphobia. Archives of General Psychiatry, 46, 127-131.
29. Miller, H., Anderson, I. M. & Deakin, J. F. W. (1995) Acute tryptophan depletion increases panic anxiety in panic disorder patients. Behavioural Pharmacology, 6 (suppl. 1), 148.
30. Nutt, D. J. & Cowen, P. J. (1987) Diazepam alters brain 5-HT function in man; implications for the acute and chronic effects of benzodiazepines. Psychological Medicine, 17, 601.
31. _ & George, D. T. (1990) Serotonin and anxiety. In Handbook of Anxiety, Vol. 3, The Neurobiology of Anxiety (ed. G. D. Burrows, M. Roth & R. Noyes), pp. 189-221. Amsterdam: Elsevier.
32. _ & Lawson, C. (1991) Panic attacks. A neurochemical overview of models and mechanisms. British Journal of Psychiatry, 10, 165-178.
33. Oehrberg, S., Christiansen, P. E., Behnke, K., et al (1995) Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. British Journal of Psychiatry, 167, 374-379.
34. Pols, H., Griez, E. & Verbug, C. (1993) Fluvoxamine-ritanserin combination in the treatment of panic anxiety with avoidance behaviour. European Neuropsychopharmacology, 3 (suppl.), 377.
35. Ramos, R. T., Gentil, V. & Gorenstein, C. (1993) Clomipramine and initial worsening in panic disorder; beyond the jitteriness syndrome. Journal of Psychopharmacology, 7, 265-269.
36. Schneier, F., Liebowitz, M., Davies, S., et al (1990) Fluoxetine in panic disorder. Journal of Clinical Psychopharmacology, 10, 119-121.
37. Sheehan, D. V., Raj, A. B., Harnett, S. K., et al (1993) The relative efficacy of high dose buspirone and alprazolam in the treatment of panic disorder; a double blind placebo controlled study. Acta Psychiatrica Scandinavica, 88, 1-11.
38. Targum, S. D. & Marshall, L. E. (1989) Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Research, 28, 295-306.
39. Van Vliet, I. M., den Boer, J., Westenberg, H. G. M., et al (1996) A double blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. Journal of Clinical Psychopharmacology, 16, 299-306.
40. Wade, A. G., Lepola, U, Koponen, H. J., et al (1997) The effect of citalopram in panic disorder. British Journal of Psychiatry, 170, 549-553.
41. Westenberg, H. & den Boer, J. (1989) Serotonin function in panic disorder effect of 1,5-hydroxytryptophan in patients and controls. Psychopharmacology, 98, 283-285.
42. _, Van Vliet, I., den Boer, J. (1992) Flesinoxan, a selective 5-HT 1a agonist, in the treatment of panic disorder. Clinical Neuropharmacology, 15 (suppl. 1b), 60.